MedPath

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

Not Applicable
Active, not recruiting
Conditions
Stroke
Interventions
Drug: Single Antiplatelet Therapy or No Therapy (Control)
Device: WATCHMAN LAAC Device Implant
Registration Number
NCT02928497
Lead Sponsor
Boston Scientific Corporation
Brief Summary

The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.

Detailed Description

The ASAP-TOO study is a prospective, randomized, multi-center, global investigation to establish the safety and effectiveness of the WATCHMAN Device for subjects with non-valvular atrial fibrillation who are deemed not suitable for anti-coagulation therapy to reduce the risk of stroke.

Subjects will be randomized in a ratio of 2 Device to 1 Control to receive the WATCHMAN LAA closure device (Device) or the control treatment of single antiplatelet medication or no medication at the discretion of the study physician (Control). All randomized subjects will follow the protocol required tests and assessments at each scheduled follow-up visit.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
481
Inclusion Criteria
  • The subject is of legal age to participate in the study per the laws of their respective geography.
  • The subject has documented paroxysmal, persistent, permanent or long-term/longstanding persistent non-valvular atrial fibrillation (i.e., the subject has not been diagnosed with rheumatic mitral valvular heart disease).
  • The subject has a calculated CHA2DS2-VASc score of 2 or greater.
  • The subject is deemed by two study physicians to be unsuitable for oral anticoagulation.
  • The subject is deemed by a study physician to be suitable for the defined protocol pharmacologic regimen of aspirin and clopidogrel therapy following WATCHMAN Closure Device implant.
  • The subject or legal representative is able to understand and willing to provide written informed consent to participate in the trial.
  • The subject is able and willing to return for required follow-up visits and examinations.
Exclusion Criteria
  • The subject is unable or unwilling to return for required follow-up visits and examinations.
  • The subject had or is planning to have any invasive cardiac procedure within 30 days prior to randomization (e.g., cardioversion, ablation).
  • The subject is planning to have any cardiac or non-cardiac invasive or surgical procedure that would necessitate stopping or modifying the protocol required medication regimen within 90 days after the WATCHMAN Closure Device implant (e.g., cardioversion, ablation, cataract surgery).
  • The subject had a prior stroke (of any cause) or TIA within the 30 days prior to randomization.
  • The subject had a prior BARC type 3 or 4 bleeding event within the 14 days prior to randomization. Lack of resolution of related clinical sequelae, or planned and pending interventions to resolve bleeding/bleeding source, are a further exclusion regardless of timing of the bleeding event.
  • The subject has a history of atrial septal repair or has an ASD/PFO device.
  • The subject has an implanted mechanical valve prosthesis in any position.
  • The subject suffers from New York Heart Association Class IV Congestive Heart Failure.
  • The subject has LVEF < 30%.
  • The subject is of childbearing potential and is, or plans to become pregnant during the time of the study (method of assessment upon study physician's discretion).
  • The subject is currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance should be brought to the attention of the sponsor to determine eligibility.
  • The subject has a life expectancy of less than two years.
  • The subject has a known or suspected hypercoagulable state.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlSingle Antiplatelet Therapy or No Therapy (Control)Single antiplatelet therapy or no therapy (Control) at the discretion of the study physician for the duration of the trial.
WATCHMAN (Device)WATCHMAN LAAC Device ImplantWATCHMAN LAAC Device implant including modified post-implant drug regimen.
Primary Outcome Measures
NameTimeMethod
Primary 7-Day Device/Procedural Safety Endpoint7 days

The primary safety endpoint is the 7-day combined rate of death, ischemic stroke, systemic embolism and complications requiring major cardiovascular or endovascular intervention.

Primary Efficacy Endpoint - time to first event of ischemic stroke or systemic embolism.5 years

The primary efficacy endpoint is the comparison of time to first event of ischemic stroke and systemic embolism.

Secondary Outcome Measures
NameTimeMethod
Secondary Endpoint - Composite of All Stroke and Cardiovascular or Unknown Death5 years

The occurrence of stroke (including ischemic and/or hemorrhagic), cardiovascular death (cardiovascular and/or unexplained cause) and systemic embolism

Secondary Endpoint - Major Bleeding5 years

The occurrence of major bleeding (defined as a BARC Type 3 or 5 event)

Trial Locations

Locations (92)

OhioHealth Research and Innovation Institute - Riverside Methodist Hospital

🇺🇸

Columbus, Ohio, United States

Cedars - Sinai Medical Center

🇺🇸

Los Angeles, California, United States

Emory University Hospital

🇺🇸

Atlanta, Georgia, United States

Union Memorial Hospital

🇺🇸

Baltimore, Maryland, United States

Sharpe Chula Vista Medical Center

🇺🇸

San Diego, California, United States

Kansas City Cardiac Arrhythmia Research

🇺🇸

Overland Park, Kansas, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

Arizona Arrhythmia Research Center

🇺🇸

Phoenix, Arizona, United States

Grandview Medical Center

🇺🇸

Birmingham, Alabama, United States

Oregon Health Sciences University

🇺🇸

Portland, Oregon, United States

Mayo Clinic Foundation

🇺🇸

Rochester, Minnesota, United States

Aurora St. Luke's Medical Center

🇺🇸

Milwaukee, Wisconsin, United States

Froedtert Memorial Lutheran Hospital

🇺🇸

Milwaukee, Wisconsin, United States

The Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

Mercy Research

🇺🇸

Saint Louis, Missouri, United States

Bay Area Cardiology Associates

🇺🇸

Tampa, Florida, United States

Huntsville Hospital

🇺🇸

Huntsville, Alabama, United States

Scripps Memorial Hospital

🇺🇸

La Jolla, California, United States

St. John's Health Center

🇺🇸

Santa Monica, California, United States

Santa Barbara Cottage Hospital

🇺🇸

Santa Barbara, California, United States

North Colorado Medical Center

🇺🇸

Greeley, Colorado, United States

St. Anthony Hospital

🇺🇸

Lakewood, Colorado, United States

Lakeland Regional Medical Center

🇺🇸

Lakeland, Florida, United States

Tampa General Hospital

🇺🇸

Tampa, Florida, United States

Evanston Hospital

🇺🇸

Evanston, Illinois, United States

Edward Hospital

🇺🇸

Naperville, Illinois, United States

St. John's Hospital

🇺🇸

Springfield, Illinois, United States

St. Vincent's Hospital

🇺🇸

Indianapolis, Indiana, United States

Mercy Hospital Medical Center

🇺🇸

West Des Moines, Iowa, United States

Heart Group at Deaconness Hospital

🇺🇸

Newburgh, Indiana, United States

Baptist Health Lexington

🇺🇸

Lexington, Kentucky, United States

Southcoast Physicians Group

🇺🇸

Fall River, Massachusetts, United States

HealthEast St. Joseph's Hospital

🇺🇸

Saint Paul, Minnesota, United States

Centracare Heart and Vascular

🇺🇸

Saint Cloud, Minnesota, United States

North Mississippi Medical Center

🇺🇸

Tupelo, Mississippi, United States

Billings Clinic

🇺🇸

Billings, Montana, United States

Catholic Medical Center

🇺🇸

Manchester, New Hampshire, United States

Cardiovascular Associates of the Delaware Valley

🇺🇸

Haddon Heights, New Jersey, United States

Mount Sinai Medical Center

🇺🇸

New York, New York, United States

The Valley Hospital

🇺🇸

Ridgewood, New Jersey, United States

St. Barnabas Medical Center

🇺🇸

Newark, New Jersey, United States

Northwell Health

🇺🇸

Staten Island, New York, United States

Rochester General Hospital

🇺🇸

Rochester, New York, United States

Carolinas Medical Center

🇺🇸

Charlotte, North Carolina, United States

Ohio State University Medical Center

🇺🇸

Columbus, Ohio, United States

Summa Health System

🇺🇸

Akron, Ohio, United States

Aultman Hospital

🇺🇸

Canton, Ohio, United States

Oklahoma Heart Institute

🇺🇸

Tulsa, Oklahoma, United States

UPMC Heart and Vascular Institute Harrisburg

🇺🇸

Harrisburg, Pennsylvania, United States

Penn State Milton S Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

University of Virginia Medical Center

🇺🇸

Charlottesville, Virginia, United States

University of Texas Houston Health Science Center

🇺🇸

The Woodlands, Texas, United States

Baylor Heart and Vascular Hospital

🇺🇸

Dallas, Texas, United States

Inova Fairfax Hospital

🇺🇸

Falls Church, Virginia, United States

Carilion Roanoke Memorial Hospital

🇺🇸

Roanoke, Virginia, United States

CHI Franciscan Health System

🇺🇸

Tacoma, Washington, United States

Aspirus Heart and Vascular Institute - Research and Education

🇺🇸

Wausau, Wisconsin, United States

PeaceHealth Southwest Medical

🇺🇸

Vancouver, Washington, United States

ZNA Middelheim

🇧🇪

Antwerp, Belgium

Onze Lieve Vrouw Ziekenhuis

🇧🇪

Aalst, Belgium

Institut universitaire de Cardiologie et de Pneumologie de Quebec

🇨🇦

Ste-foy, Canada

Ottawa Heart Institute

🇨🇦

Ottawa, Canada

Vancouver General Hospital

🇨🇦

Vancouver, Canada

Na Homolce Hospital

🇨🇿

Prague, Czechia

Aarhus University Hospital

🇩🇰

Aarhus N, Denmark

Universitaetsklinikum Dusseldorf

🇩🇪

Dusseldorf, Germany

Rigshospitalet Copenhagen

🇩🇰

Copenhagen, Denmark

St.Johann Nepomuk Katholisches Hospitalvereinigung Thüringen GmbH

🇩🇪

Erfurt, Germany

Cardiologicum Hamburg Praxis Wandsbek

🇩🇪

Hamburg, Germany

Cardioangiologisches Centrum Bethanien

🇩🇪

Frankfurt, Germany

Fondazione Toscana Gabriele Monasterio

🇮🇹

Massa, Italy

Herzzentrum Universität Leipzig

🇩🇪

Leipzig, Germany

Royal Sussex County Hospital

🇬🇧

Brighton, United Kingdom

Royal Victoria Hospital

🇬🇧

Belfast, United Kingdom

John Radcliffe Hospital

🇬🇧

Oxford, United Kingdom

Guys and St. Thomas NHS Foundation Trust

🇬🇧

London, United Kingdom

The Brompton Hospital

🇬🇧

London, United Kingdom

Sarasota Memorial Hospital

🇺🇸

Sarasota, Florida, United States

Tallahassee Memorial Hospital

🇺🇸

Tallahassee, Florida, United States

Lehigh Valley Hospital

🇺🇸

Allentown, Pennsylvania, United States

Dartmouth Hitchcock Medical Center

🇺🇸

Lebanon, New Hampshire, United States

Advocate Christ Medical Center

🇺🇸

Oak Lawn, Illinois, United States

Delray Medical Center

🇺🇸

Delray Beach, Florida, United States

York Hospital

🇺🇸

York, Pennsylvania, United States

Saint Thomas Health

🇺🇸

Nashville, Tennessee, United States

Maine Medical Center

🇺🇸

Portland, Maine, United States

Arrhythmia Research Group

🇺🇸

Jonesboro, Arkansas, United States

Washington Hospital Center

🇺🇸

Washington, District of Columbia, United States

St. Antonius Ziekenhuis

🇳🇱

Nieuwegein, Netherlands

Northwestern Memorial Hospital

🇺🇸

Chicago, Illinois, United States

Medisch Spectrum Twente

🇳🇱

Enschede, Netherlands

St. Luke's Hospital of Kansas City

🇺🇸

Kansas City, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath